MDMA/FDA meeting
This article was originally published in The Gray Sheet
Executive Summary
Medical Device Manufacturers Association President Larry Holden and Director of Federal Affairs Mark Leahey plan to meet with FDA Acting Commissioner Lester Crawford and CDRH Director David Feigal June 4. Among probable discussion topics are a device user fee proposal negotiated by trade group AdvaMed and FDA. The proposal was recently excluded from bioterrorism legislation but could still be reconsidered by Congress this session along with Greenwood/Eshoo device reforms (1"The Gray Sheet" May 27, 2002, p. 3)...
You may also be interested in...
Kennedy To Industry: User Fees Still In Play If Third Party Sits This One Out
Industry supporters of medical device user fees are assuming a formidable challenge by linking the legislative proposal with the "Medical Device Amendments of 2001" (HR 3580), introduced by Reps. Jim Greenwood (R-Penn.) and Anna Eshoo (D-Calif.)
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.